Financial Gravity Companies’s Inovio Pharmaceuticals INO Stock Holding History

Financial Gravity Companies’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$0	Buy	+3	New	+$182	﹤0.01%	1448

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Financial Gravity Companies's INO Position: Q4 2018 in Review

Financial Gravity Companies opened a new position in Inovio Pharmaceuticals (INO) in Q4 2018: 3 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1448 among its holdings.

125 funds tracked by Wall St. Rank hold INO as of Q4 2018.

Financial Gravity Companies held 3 shares of Inovio Pharmaceuticals worth $0 as of Q4 2018.
Inovio Pharmaceuticals was a new Financial Gravity Companies position in Q4 2018.
Inovio Pharmaceuticals made up ﹤0.01% of Financial Gravity Companies's portfolio in Q4 2018, its #1448 holding.
125 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2018.

Based on Financial Gravity Companies's 13F filing for Q4 2018, filed 4 Feb 2019.